Initial studies in MMR deficient gynecologic cancers have shown that these tumors do respond to anti-PD-1 immunotherapy, however these initial studies were designed to include any cancer type with known MMR deficiency, and therefore the overall numbers of gynecologic cancers included were low [139,140]. This evidence concerns the gene PDCD1 and cancer.